Upadacitinib Achieves Consistent Skin Clearance Across Body Regions in Real-World AD-VISE Study
A real-world analysis from the AD-VISE study demonstrates that upadacitinib delivers consistent improvements in skin clearance across multiple body regions in patients with atopic dermatitis (AD), regardless of baseline disease severity or prior biologic use.
This observational, prospective, multi-country study evaluated the effectiveness of upadacitinib in routine clinical practice, focusing on outcomes by body region and prior biologic exposure. Patients were stratified by baseline Eczema Area and Severity Index (EASI) scores across 4 body regions (head and neck, upper limbs, trunk, lower limbs) and categorized as biologic-naive or biologic-experienced. Outcomes included the proportion of patients achieving EASI 75, 90, and 100 at 2, 4, and 6 months of treatment.
Across all body regions, treatment responses were consistent. Approximately 70% of patients with head and neck involvement achieved EASI 75 at 6 months, while 55.9% to 59.3% achieved EASI 90 and 41.1% to 48.3% achieved complete clearance (EASI 100). Similar trends were observed in the upper limbs, trunk, and lower limbs, where most patients (71.8% to 89.3%) reached EASI 75, a majority (62.7% to 76.7%) achieved EASI 90, and 47.8% to 67.8% achieved EASI 100 at 6 months.
Importantly, outcomes were consistent regardless of prior biologic exposure and baseline disease severity, suggesting broad effectiveness across patient subgroups and anatomical sites.
“In this interim real-world analysis from the AD-VISE study, a majority of patients with atopic dermatitis treated with upadacitinib achieved EASI 90 by 6 months, across all body regions, with rates of response ranging from 55.9% to 73.2%,” the authors concluded. “Across body regions, improvements in skin clearance with upadacitinib was largely consistent regardless of baseline disease severity or prior biologic experience.”
These findings reinforce the real-world utility of upadacitinib as a systemic option for achieving rapid and consistent skin clearance across diverse AD patient populations.
Reference
Gooderham M, Lang C, Lynde CW, et al. Real-world effectiveness of upadacitinib for atopic dermatitis across body regions by prior biologic exposure in the AD-VISE study. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, Colorado.
